Group 1 - The Carillon Scout Mid Cap Fund's second quarter 2025 investor letter indicates that the Russell Midcap Index experienced positive returns despite a sell-off in early April due to tariff announcements [1] - The delay in collecting additional tariffs allowed trading partners more time to negotiate better terms, which may have positively influenced market conditions [1] - Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is highlighted as a key stock, with a one-month return of 1.99% and a 52-week loss of 1.25%, closing at $103.85 per share with a market capitalization of $20.572 billion [2] Group 2 - Zimmer Biomet Holdings, Inc. reported net sales of $2.077 billion in the second quarter, reflecting a 7% increase on a reported basis [4] - The company faced challenges, including lowered guidance due to dilution from a recent acquisition and market share loss in knee replacement products, despite an overall solid earnings report [3] - The lowered guidance is viewed as a one-time reset, with expectations for revenue growth to accelerate due to an upcoming new release cycle and potential positive impacts from tariff news [3]